Nitroprusside and phenylephrine

PreclinicalSmall molecule

Nitroprusside and phenylephrine is one of 41 small molecule programs targeting Uterine Fibroid. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine FibroidActive, not recruiting

Uterine FibroidPreclinical

Active, not recruiting

Competition

Competitive Landscape

53 competitors in Uterine Fibroid

#DrugCompanyPhaseTrials

Orilissa

AbbVie

Approved

7 2

Mifeprex

DDanco

Approved

4 3

Lupron

Femara

Cytotec

Cyklokapron

1 7

Levonorgestrel IUS

Bayer

Approved

1 8

Esbriet

LLegacy Health System

Approved

—9

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—10

Zoladex

TTerSera Therapeutics LLC

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Uterine Fibroid1 trial

Vascular Function and Uterine Fibroids

Completed·MMayo Clinic··NCT02123069·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nitroprusside and phenylephrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nitroprusside and phenylephrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nitroprusside and phenylephrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMayo Clinic

Nitroprusside and phenylephrine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Uterine Fibroid1 trial

References

Drug Info

Quick Facts

Related News